As local hospitals try to offer package deals with upfront prices on joint replacement surgeries, they're struggling with the reality that patients' other health conditions can significantly increase their cost of care.
The farmers won't be able to take full advantage of the seeds until the EPA issues a second ruling allowing the use of weed killer Enlist. The EPA has said it will rule this fall on Indianapolis-based Dow AgroSciences' application to market the chemical.
Strong leadership is needed for the urban Indianapolis tech park to hit its high potential.
A new study finds that Obamacare boosted enrollment in Indiana’s individual insurance market significantly over what it would have been without the law, but also caused premiums to spike.
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
Conservatives, after waging war on Obamacare, including its large expansion of Medicaid, are starting to try to propose alternative, conservative ways to achieve its key goals.
Companion Diagnostics Inc., a biotech company that relocated to Indiana from Connecticut in 2010, has entered bankruptcy reorganization while it tries to develop a therapy for inflammation.
Indiana does not appear to be enjoying the rest of the nation’s slowdown in health care spending. Year-to-year growth in Indiana hit 6 percent in 2012 versus 4.5 percent for the nation.
Just three months before the parent company of AIT Laboratories was sold in 2009 to its employees for $90 million, it was appraised for $17.1 million, according to a U.S. Department of Labor lawsuit.
Indiana has 58 percent more nursing homes per resident and spends an extra $1 billion per year on care in nursing homes than the average for the rest of the country.
Anthem patients in five U.S. cities, including Indianapolis, spent $220 less per MRI scan after Anthem told them of lower-cost facilities. In response, hospital-owned MRI facilities cut their prices.
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.
State and local governments hand out $921 million per year to entice business to add jobs. The Medicaid expansion is estimated to cost no more than $279 million per year.
In two to three years, primary care clinics could be popping up in Walmart stores in rural Indiana while most rural Indiana hospitals will offer little to no inpatient services. That’s dramatically different from what we’re used to.
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Hendricks County finds pay dirt pitching skills of racing industry to medical device manufacturers.
In spite of the beaucoup bucks in the pharma sector, patients, along with their families and committed advocates, are turning out to be better sources of funding for early stage companies because they tolerate risk better than drug companies and investors.
Gov. Mike Pence thinks his HIP 2.0 plan would reform Medicaid in line with conservative principles. To the extent the Obama administration agrees, that’s the biggest hurdle to get the plan approved.
